A Phase 1 Study of LY2127399 in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Tabalumab (Primary) ; Bortezomib; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Eli Lilly
- 09 Feb 2016 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
- 19 Aug 2015 Planned End Date changed from 1 Dec 2015 to 1 Aug 2015, according to ClinicalTrials.gov record.
- 15 Jul 2015 Planned End Date changed from 1 Oct 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.